Celcuity Inc. (NASDAQ: CELC) presented updated results from its Phase 3 VIKTORIA-1 trial evaluating gedatolisib in patients with hormone receptor ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE